ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E22.06 EPS (ttm)6.97 Insider Own0.10% Shs Outstand1.77B Perf Week0.96%
Market Cap266.63B Forward P/E12.86 EPS next Y11.96 Insider Trans-32.03% Shs Float1.77B Perf Month5.33%
Income12.40B PEG11.82 EPS next Q3.43 Inst Own70.90% Short Float0.72% Perf Quarter-5.13%
Sales56.73B P/S4.70 EPS this Y137.00% Inst Trans2.67% Short Ratio1.73 Perf Half Y13.15%
Book/sh9.19 P/B16.74 EPS next Y-14.68% ROA8.50% Target Price163.01 Perf Year34.61%
Cash/sh4.37 P/C35.21 EPS next 5Y1.87% ROE85.80% 52W Range105.56 - 175.91 Perf YTD13.59%
Dividend5.64 P/FCF21.19 EPS past 5Y12.20% ROI17.90% 52W High-12.57% Beta0.77
Dividend %3.67% Quick Ratio0.70 Sales past 5Y17.00% Gross Margin69.80% 52W Low45.70% ATR3.58
Employees50000 Current Ratio0.80 Sales Q/Q4.10% Oper. Margin32.70% RSI (14)60.84 Volatility2.01% 2.29%
OptionableYes Debt/Eq4.51 EPS Q/Q26.20% Profit Margin21.90% Rel Volume0.63 Prev Close153.16
ShortableYes LT Debt/Eq3.90 EarningsApr 29 BMO Payout75.90% Avg Volume7.36M Price153.80
Recom2.10 SMA205.13% SMA502.61% SMA20012.55% Volume4,619,549 Change0.42%
May-23-22Initiated SVB Leerink Underperform $140
May-06-22Downgrade Daiwa Securities Outperform → Neutral $150
Apr-06-22Resumed Morgan Stanley Overweight $192
Feb-28-22Downgrade UBS Buy → Neutral $129 → $147
Feb-03-22Reiterated Goldman Neutral $117 → $122
Feb-03-22Reiterated BofA Securities Neutral $135 → $138
Feb-03-22Reiterated BMO Capital Markets Outperform $153 → $154
Feb-03-22Reiterated Barclays Equal Weight $133 → $150
Jan-13-22Initiated Redburn Buy
Jan-12-22Reiterated BMO Capital Markets Outperform $134 → $153
Dec-09-21Resumed Wells Fargo Overweight $165
Nov-23-21Upgrade Societe Generale Hold → Buy $172
Jul-27-21Resumed Truist Buy $118
Apr-07-21Resumed RBC Capital Mkts Outperform $135
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
Jul-02-22 05:57AM  
Jul-01-22 03:05PM  
10:00AM  
05:52AM  
Jun-30-22 12:37PM  
11:00AM  
09:15AM  
05:41AM  
Jun-29-22 11:23AM  
09:00AM  
Jun-27-22 05:45PM  
12:10PM  
11:08AM  
11:01AM  
09:55AM  
08:00AM  
06:13AM  
02:00AM  
Jun-26-22 05:57AM  
Jun-25-22 04:00AM  
Jun-24-22 09:19AM  
08:00AM  
Jun-23-22 03:43PM  
11:07AM  
Jun-22-22 10:32AM  
08:00AM  
06:20AM  
Jun-21-22 10:35AM  
08:00AM  
Jun-20-22 05:45PM  
10:06AM  
Jun-19-22 08:10AM  
Jun-17-22 09:00AM  
08:00AM  
05:06AM  
Jun-16-22 09:00AM  
Jun-14-22 05:45PM  
10:41AM  
08:04AM  
05:51AM  
Jun-13-22 02:49PM  
12:25PM  
12:11PM  
08:00AM  
Jun-11-22 08:45AM  
06:43AM  
Jun-10-22 06:11AM  
03:15AM  
01:05AM  
Jun-08-22 07:45AM  
Jun-07-22 11:45AM  
11:00AM  
08:00AM  
Jun-06-22 05:45PM  
11:27AM  
Jun-05-22 02:29PM  
07:04AM  
Jun-04-22 11:23AM  
Jun-03-22 11:45AM  
09:00AM  
08:00AM  
Jun-01-22 11:15AM  
10:35AM  
05:52AM  
May-30-22 09:25AM  
May-29-22 07:31AM  
May-27-22 10:36AM  
03:15AM  
03:00AM  
May-26-22 06:00PM  
02:19PM  
10:41AM  
07:51AM  
06:00AM  
May-25-22 12:05PM  
11:00AM  
09:11AM  
08:00AM  
May-24-22 01:48PM  
01:02PM  
12:04PM  
10:00AM  
08:00AM  
May-23-22 11:46AM  
08:00AM  
07:01AM  
02:00AM  
May-21-22 11:00AM  
07:31AM  
May-20-22 09:17AM  
09:00AM  
08:50AM  
08:15AM  
May-19-22 12:00PM  
06:40AM  
06:30AM  
May-18-22 06:16PM  
09:39AM  
09:06AM  
May-17-22 11:58AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SEVERINO MICHAELVice ChairmanMay 23Option Exercise108.9979,8018,697,627231,904May 25 04:58 PM
SEVERINO MICHAELVice ChairmanMay 23Sale150.9079,80112,041,780152,103May 25 04:58 PM
SEVERINO MICHAELVice ChairmanMay 17Option Exercise88.38100,0008,837,929252,103May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 17Sale154.04100,00015,404,400152,103May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 16Option Exercise66.50100,0006,650,277252,103May 18 05:12 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMay 16Option Exercise54.8683,9604,606,046100,583May 18 05:12 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMay 16Sale155.0083,96013,013,80016,623May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 16Sale154.45100,00015,445,089152,103May 18 05:12 PM
SEVERINO MICHAELVice ChairmanMay 10Option Exercise59.60100,0005,960,468252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 10Sale152.28100,00015,227,966152,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 09Option Exercise56.21100,0005,621,478252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 09Sale150.28100,00015,027,710152,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 06Option Exercise54.55100,0005,454,790252,103May 10 05:05 PM
SEVERINO MICHAELVice ChairmanMay 06Sale150.81100,00015,080,612152,103May 10 05:05 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 24Option Exercise58.8827,6901,630,38788,631Mar 25 05:09 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 24Sale159.2027,6904,408,37560,941Mar 25 05:09 PM
Durkin Brian LVP, ControllerMar 09Option Exercise79.0211,682923,11237,722Mar 11 05:05 PM
Durkin Brian LVP, ControllerMar 09Sale150.0118,6282,794,30119,094Mar 11 05:05 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMar 01Sale148.2615,0002,223,83641,623Mar 01 06:14 PM
Michael Robert A.Vice ChairmanMar 01Sale148.2543,1056,390,24737,877Mar 01 06:07 PM
Gosebruch Henry OEVP, Chief Strategy OfficerMar 01Sale147.2925,0003,682,18916,623Mar 02 05:03 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerMar 01Sale148.2521,4883,185,59960,941Mar 01 06:08 PM
Strom Carrie CSVP & Pres Global Allerg AesthFeb 07Sale141.172,396338,24342,499Feb 08 05:13 PM
Durkin Brian LVP, ControllerDec 20Option Exercise61.367,180440,56528,295Dec 21 05:29 PM
Durkin Brian LVP, ControllerDec 20Sale128.5111,7901,515,13316,505Dec 21 05:29 PM
Schumacher Laura JVice ChairmanDec 17Option Exercise57.14181,67010,381,361394,673Dec 21 05:21 PM
Schumacher Laura JVice ChairmanDec 17Sale130.24181,67023,660,678213,003Dec 21 05:21 PM
Stewart Jeffrey RyanEVP, Chief Commercial OfficerDec 15Sale128.002,152275,45647,104Dec 17 05:01 PM
Sorg Elaine K.SVP, US Commercial OperationsDec 13Sale125.856,458812,7390Dec 14 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 09Option Exercise61.36174,10010,682,776550,697Dec 10 05:02 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 09Sale123.23174,10021,453,641376,597Dec 10 05:02 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerDec 06Option Exercise58.8850,3502,964,60850,350Dec 08 05:01 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerDec 06Sale120.0050,3506,042,0000Dec 08 05:01 PM
AUSTIN ROXANNE SDirectorNov 03Sale117.2320,0002,344,60049,284Nov 04 05:35 PM
AUSTIN ROXANNE SDirectorNov 02Sale116.3851,8446,033,38469,284Nov 04 05:35 PM
Sorg Elaine K.SVP, US Commercial OperationsAug 23Option Exercise114.367,080809,66918,675Aug 25 06:08 PM
Strom Carrie CSVP & Pres Global Allerg AesthAug 23Sale120.005,057606,84051,047Aug 25 06:08 PM
Sorg Elaine K.SVP, US Commercial OperationsAug 23Sale120.0013,0801,569,60011,595Aug 25 06:08 PM